Aurinia Pharmaceuticals (($AUPH)) has held its Q3 earnings call. Read on for the main highlights of the call. Aurinia Pharmaceuticals’ recent ...

Aurinia alleges that Tidmarsh’s statements were not only inaccurate but also motivated by a personal vendetta against Kevin ...

The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.

A growing number of FDA employees are eyeing the exits as chaos and uncertainty sweep through the agency, according to ...

An alleged extortion attempt, a petty yearslong grudge, shocking social media posts, and ominous text messages make up the ...

Ars Technica has been separating the signal from the noise for over 25 years. With our unique combination of technical ...

The resignation of head drug regulator George Tidmarsh comes amid concerns about conduct related to the lupus nephritis drug ...

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...

Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request ...

The drama continued Monday with senior FDA leaders as more details emerged about former Center for Drug Evaluation and ...

Dr. George Tidmarsh, who joined the FDA in July, stepped down Sunday, The New York Times reported. His resignation came just ...

Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s ...